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Proliferative vitreoretinopathy (PVR) develops as a complication of retinal
detachment surgery and represents a devastating condition leading to seri-
ous vision loss. A good animal model that permits extensive functional
studies and drug testing is crucial in finding better therapeutic modalities
for PVR. A previously established mouse model, using dispase injection,
was analyzed from the proteomic point of view, examining global protein
profile changes by 2D electrophoresis, image analysis and HPLC–tandem
mass spectrometry-based protein identification. The easy applicability of
the mouse model was used to study the role of transglutaminase 2 (TG2)
in PVR formation by proteomic examination of dispase-induced TG2
knockout vitreous samples. Our data demonstrate that, despite the altered
appearance of crystallin proteins, the lack of TG2 did not prevent the
development of PVR.
Proliferative vitreoretinopathy (PVR) develops as a
complication in 8–25% of patients undergoing pri-
mary retinal detachment surgery. It is a multifacto-
rial disease induced by a variety of factors [1]. A
hallmark of PVR is the aggressive proliferation of
glial and retinal pigment epithelium (RPE) cells
originating from retinal breaks or holes, making
PVR an unsolved challenge. The epithelial-to-
mesenchymal transition activated by different
serum-derived or vitreal factors is responsible for
the formation of epiretinal membrane and hence
PVR pathogenesis [2,3]. Recently, we have shown
activation of neural progenitor cells in human eyes
with PVR near the pars plana region, from which
only the glial population seemed to respond to reti-
nal injury by targeted migration into the vitreous
[4].
Extracellular matrix (ECM) deposition in PVR
appears with the concomitant release of matrix-degrad-
ing enzymes including matrix metalloproteases
(MMPs) with a likely function to prevent excess pro-
tein deposition [5].
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Transglutaminase 2 (TG2), the most widely studied
member of the transglutaminase family [6], has various
functions: it can participate in the apoptosis process; it
can be present on the cell surface and in the ECM;
and it can modulate tissue stability and cell–matrix
interactions [7,8]. TG2 plays an important role in
wound healing; its absence may cause delayed wound
closure that, to a certain extent, can be valuable in
reducing scar formation [9,10]. Transglutaminases are
expressed in many types of normal ocular tissues
[11,12] and TG2 is present in human PVR membranes.
In PVR membranes, TG2 crosslinking of ECM pro-
teins could prevent their degradation by the elevated
protease activities and therefore may have an impor-
tant role in the onset of PVR [5].
Although a number of proteins were identified in
normal human vitreous [13,14] and the potential con-
tribution of genetic components to PVR has been
recently described by some research groups, only the
alterations of a few proteins and genes has been clari-
fied in PVR formation [15,16]. 2D gel electrophoresis
(2-DE) coupled with mass spectrometry (MS)-based
protein identification, the widely used proteomic tool
for the analysis of protein profile changes [17], has
been applied to study the human vitreal proteins char-
acteristic of PVR formation, and the presence of extra-
cellular proteins, such as zinc finger protein 670 and
prostaglandin D2 synthase, was demonstrated [18]. In
human vitreous samples originating from patients with
PVR, 516 proteins have been identified by MS and
increased levels of extracellular proteins and reduced
levels of cytoskeletal proteins have been observed [19].
Considering the serious sight-threatening feature
and high incidence of PVR, there is increasing pressure
to develop better medications for the treatment of this
eye condition. In order to facilitate drug discovery,
various animal models have been generated in the
past. Most of the models induce PVR in rabbit, rat or
piglet eyes either by injecting cells or by performing
very invasive surgical procedures such as retinotomy
[20–22]. Our group used a suitable mouse model for
PVR by injecting dispase into mouse eyes, since it is
fast, reproducible and avoids use of more invasive sur-
gical approaches [4]. The presence of PVR in mice was
demonstrated by imaging techniques in our wider col-
laborative network [4], but the exact proteomic signa-
ture was not examined in detail.
In this work, as a continuation of the previous
study, we have analyzed the vitreal protein profile of
dispase-treated mice in order to examine the protein
profile changes. A good animal model is increasingly
important to elucidate the exact molecular pathomech-
anism of the PVR and can help foster drug discovery
and drug testing providing suitable drug candidates
for successful PVR therapy.
Materials and methods
All chemicals used for 2-DE and MS were of electrophore-
sis or liquid chromatography (LC)–MS grade and were
purchased from Sigma-Aldrich (St. Louis, MO, USA) unless
stated otherwise.
Animal samples
A mouse model of PVR was used by applying an intravit-
real injection of a proteolytic enzyme, dispase. This model
is known to induce glial activation as well as both epi- and
subretinal membrane formation [23,24]. All animal experi-
ments were performed according to the Association for
Research in Vision and Ophthalmology (ARVO) Statement
for the Use of Animals in Ophthalmic and Vision
Research. Study protocols were approved by the Animal
Care Committee of the University of Debrecen. Female
4- to 6-month-old wild-type (WT; C57/BL6, n = 6) and
TG2KO mice (n = 6) were anesthetized with pentobarbital
(90 mgkg1, i.p.), and also received one drop of 1% pro-
caine hydrochloride (Novocaine, EGIS, Budapest, Hun-
gary) for local anesthesia and one drop of tropicamide
(Mydrum, Chauvin Aubeans, Montpellier, France) for iris
dilation. Four microliters of dispase (Sigma-Aldrich; 0.4
UlL1, dissolved in sterile physiological saline solution)
was injected intravitreally into the right eyes under stere-
omicroscopic control (Ctrl) using an automatic pipette fit-
ted with a 30G 1/6 needle, as previously described [23]. Ctrl
animals received 4 lL of sterile physiological saline solu-
tion. Stratus optical coherence tomography images (OCT;
Carl Zeiss Meditec, Dublin, CA, USA) were taken follow-
ing injections to confirm PVR induction and monitor
disease progression (results not shown here). Ctrl and
dispase-treated mice were sacrificed at the 14th day follow-
ing injections when signs of PVR formation were evident:
presence of epiretinal membrane and/or retinal detachment
on OCT examination.
Sample preparation and purification
The vitreous bodies of mice were isolated after guillotine
removal of the cornea together with a scleral galler using a
scalpel blade, followed by removal of the lens. After solubi-
lization of the vitreous body with lysis buffer (pH 8.5) con-
taining 7 M urea, 30 mM Tris, 2 M thiourea and 4%
CHAPS, the lysates were sonicated in an ice-cold water
bath for 5 min and centrifuged at 16 900 g for 10 min at
4 °C. The supernatants were transferred to LoBind Eppen-
dorf tubes and purified by Ready-Prep 2-D CleanUp Kit
(Bio-Rad Laboratories, Hercules, CA, USA) according to
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the manufacturer’s protocol. Briefly, following precipitation
and centrifugation, the pellets were dried and resuspended
in 240 lL rehydration buffer containing 7 M urea, 2 M
thiourea, 4% w/v CHAPS, 1% dithiothreitol (DTT), 2% v/v
Bio-Lyte (Bio-Rad) and 0.001% bromophenol blue, and
used immediately for isoelectric focusing.
2D gel electrophoresis
Three vitreous samples originating from each group (WT
Ctrl, WT PVR, TG2 knock-out (KO) Ctrl, TG2 KO PVR)
were subjected to 2-DE. First immobilized pH gradient
(IPG) strips with an IPG (24 cm, pH 4–7; Bio-Rad) were
rehydrated with extracted vitreous proteins using passive
rehydration at 20 °C overnight. This was followed by iso-
electric focusing performed by applying 300 V for 3 h,
which was gradually increased to 3500 V in 5 h and then
held at 3500 V for 18 h. After isoelectric focusing, the IPG
strips were immediately placed at 70 °C until equilibra-
tion. The IPG strips were equilibrated for 15 min in equili-
bration buffer (500 mM Tris/HCl, pH 8.5, 6 M urea, 2%
SDS, 20% glycerol) containing 0.6% DTT and for 15 min
in equilibration buffer containing 1.2% iodoacetamide. In
the second dimension, the strips were laid on top of 12%
polyacrylamide gels and covered with agarose. Using a Pro-
tean Plus Dodeca Cell (Bio-Rad) the electrophoresis was
carried out at 100 mA per gel for 24 h until the bromophe-
nol blue dye reached the bottom of the gel. All 12 gels
were run together under the same conditions. Proteins
were stained using in-house prepared ruthenium II
tris(bathophenanthroline disulfonate) fluorescent dye [25]
and gel images were recorded using Pharos FX Plus Molecu-
lar Imager (Bio-Rad). Three biological replicates were
analyzed in all cases, the samples from the Ctrl and the dis-
pase-treated groups were processed together on the same day.
Quantitative analysis of protein expression
profile using Delta2D software
Protein spot patterns were evaluated with DELTA2D (Deco-
don, Greifswald, Germany) software version 4.4. Briefly,
the gel images were grouped as follows: (a) dispase-treated
WT (WT PVR), (b) physiological saline-treated WT (WT
Ctrl), (c) dispase-treated TG2 KO (TG2 KO PVR) and (d)
physiological saline-treated TG2 KO (TG2 KO Ctrl). Gel
images of three biological replicates were included in each
group having altogether 12 images. Two data analysis sets
were created: (a) in the first set, the WT Ctrl vs. WT PVR
gel images were studied, while (b) in the second set, the
TG2 KO Ctrl vs. TG2 KO PVR gel images were examined.
Protein spot patterns of gels from each of the Ctrl and
PVR groups were matched using the exact mode matching
protocol and the group warping strategy. Using union
mode, a fused image containing all spots present on all of
the gels included in the data analysis set was generated.
Every spot on each gel was quantified and the total quan-
tity of the spots was considered as 100. The spot intensity
was normalized according to the total intensity of all spots
in each gel and was given as normalized spot volume (%V)
compared with the total intensity. The mean of the normal-
ized volume was calculated in the PVR group and divided
by the mean of the normalized volume over the Ctrl group
and the fold change values were calculated.
Statistical analysis
The quantification table was generated by the Delta2D
software and the level of significance was determined auto-
matically using Student’s t test. Those spots were consid-
ered significant where the P < 0.05 criterion was valid.
In-gel digestion
The protein spots showing significantly different intensities
upon dispase treatment were excised manually from the 2D
gels using a pipette tip and were digested in-gel with tryp-
sin. First, the gel spots were cut into 1 9 1 mm pieces and
were destained using a 1 : 1 ratio of 25 mM ammonium
bicarbonate pH 8.5 and 50% acetonitrile, followed by
reduction with 20 mM DTT for 1 h at 56 °C. The alkyla-
tion was performed using 55 mM iodoacetamide for 45 min
at room temperature in the dark, followed by digestion
with 100 ng stabilized MS grade trypsin (ABSciex, Califor-
nia, USA) overnight at 37 °C. The reaction was stopped by
adding formic acid (FA). The tryptic peptides were
extracted from the gel pieces, dried in a vacuum concentra-
tor and kept at 20 °C until MS analysis.
Protein identification by HPLC–tandem mass
spectrometry
For protein identification, the samples were redissolved in
10 lL 1% FA, separated on Easy nLCII (Bruker, Coven-
try, UK) nanoHPLC and analyzed using a 4000QTRAP
(ABSciex) mass spectrometer. The chromatographic separa-
tion was performed at a flow rate of 300 nLmin1 in a
90 min water/acetonitrile gradient. The mobile phase A
was 0.1% FA in LC-MS grade water (Sigma), while the
mobile phase B was acetonitrile with 0.1% FA. The peptide
mixture was loaded onto a 5 mm 9 0.3 mm Zorbax 300SB
desalting column packed with 5 lm particle size C18 resin
(Agilent Technologies, Santa Clara, CA, USA). Thereafter,
the peptides were separated on a 150 mm 9 75 lm Zorbax
300SB analytical column (300 A particle size, 3.5 lm pore
size C18 resin; Agilent).
The tandem mass spectrometry (MS/MS) analysis was
performed in positive ion mode and the information-depen-
dent acquisition method was applied. For protein
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identification, collision-induced dissociation spectra were
obtained in enhanced product-ion mode at a scan rate of
4000 amus1 and the rolling collision energy was utilized
with the maximum of 80 eV. After the first mass scan
(mass range 400–1700 amu), the charge state of the precur-
sor ions was established by enhanced resolution and the
MS/MS spectra of the two most intensive ions were
recorded (mass range 100–1900 amu). The cycle time was
5.5 s, the spray voltage was 2800 V, the ion source gas was
50 psi, the curtain gas was 20 psi and the source tempera-
ture was 70 °C.
For protein identification based on the recorded MS/MS
spectra, the PROTEINPILOT 4.5 software (ABSciex) and the
UniProtKB/Swiss-Prot database (version 2014.06.11,
545536 entry) was used. The minimum criteria for protein
identification were the presence of two peptides per protein
with at least 95% confidence.
Results
Proteins characteristic for PVR induction upon
dispase treatment in WT mice
To study the proteins involved in the pathogenesis of
PVR in mice, WT C57/BL6 mice were used and PVR
was induced by dispase injection. 2-DE was carried
out on vitreous samples originating from three Ctrl
and three dispase-treated WT mice. Gels were stained
with homemade ruthenium II tris(bathophenanthroline
disulfonate) [25] and the gel images were analyzed
using DELTA2D (Decodon) software. The WT Ctrl
group was created from the three gel images originat-
ing from physiological saline-treated samples and the
WT PVR group was created from the three gel images
originating from dispase-treated samples. A fused
image was generated by superimposing all gel images,
and altogether 698 spots could be detected on the
fused image (Fig. 1). The intensity of each spot on
each gel was determined and the fold change between
the groups was calculated. The intensity of 30 out of
698 spots showed significant (P < 0.05) changes as a
result of dispase treatment and these 30 spots were
excised from the gel, subjected to in-gel trypsin diges-
tion and subsequent HPLC-MS/MS-based protein
identification (Tables 1 and S1). The comparison
between the WT Ctrl vs. WT PVR group aimed to get
information about the proteins for which altered
appearance is associated with PVR.
In case of 19 spots, different forms of crystallins
were identified. Crystallins are known as stress pro-
teins, from which three main types, a, b and c, can be
distinguished. The number of spots containing a-crys-
tallin A was the highest (eight out of 19) and the
amount of various forms of crystallins except a-crys-
tallin B (Cryab) decreased. The level of some intracel-
lular proteins, such as a-enolase (Eno1), tubulin,
creatine kinase B-type (Ckb), glutamine synthetase
(Glul), G protein, heterogeneous nuclear ribonucleo-
protein H (Hnrnph1), heat shock protein b-1 (Hspb1),
grifin (Grifin) and fatty-acid binding protein 5, was
reduced in the dispase-treated WT samples compared
with the physiological saline treated ones (Table 1). In
case of spots 11, 12, 13, 14, 16, 17, 18, 22 and 24,
more than one protein with similar peptide counts
reflecting almost equal quantities of each protein was
detected. Therefore, the combined effect of these pro-
teins could be monitored in such cases, and no infor-
mation on the contribution of each individual protein
to the spot intensity changes could be observed.
Proteins characteristic for PVR induction upon
dispase treatment in TG2KO mice
Mice models are widely used to examine the function
of well-defined proteins as far as the KO animals for
the studied protein can easily be created. Our group
previously studied TG2, a multifunctional enzyme hav-
ing diverse roles in different physiological and patho-
logical conditions [26]. TG2 has been shown to be
present in PVR membranes [5], but the role of this
enzyme in PVR has not been examined in detail. In
order to demonstrate the feasibility of the mouse PVR
model in elucidating the role of TG2 in PVR, dispase
and physiological saline, respectively, were injected
into the eyes of TG2 KO animals. The strategy for the
study of WT Ctrl and WT PVR samples was applied
in the case of TG2 KO samples as well; the vitreous
samples were subjected to 2D electrophoresis followed
by protein staining and image analysis. Due to a tech-
nical problem, on one of the gel images from the phys-
iological saline-treated TG2 KO mouse eyes very few
spots could be detected, so this gel image was excluded
from further analyses. The images from the TG2 KO
Ctrl group created from the two gel images originating
from physiological saline-treated TG2 KO mouse eyes
and from the TG2 KO PVR group created from the
three gel images originating from dispase-treated TG2
KO mouse eyes were superimposed to generate the
fused image (Fig. 2). Altogether 866 spots were
detected, out of which 97 showed significant (P < 0.05)
changes in their intensities upon dispase treatment.
The amount of proteins in 33 spots increased, while in
64 spots it decreased. Interestingly, some spots within
the basic pH and lower molecular mass region of the
gels could be detected only in case of TG2 KO PVR
samples; in spite of otherwise good quality of protein
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separation, very few spots were visible in the gel region
corresponding to basic, low molecular mass proteins in
the case of the saline-treated samples (Fig. 2B). The
spots showing significantly different intensities were
cut out and 37 of them were subjected to protein iden-
tification using HPLC-MS/MS (Table S1).
In accordance with the previous results, most of
the spots showing altered intensity changes upon dis-
pase treatment contained a-crystallin, but in this
case, their level was increased upon the treatment
(Table 2 and Fig. 3). The amount of tubulin, hetero-
geneous nuclear ribonucleoprotein and G-protein was
reduced upon dispase treatment, being in accordance
with previous results obtained by the analysis of WT
mice. The amount of the glycolytic enzyme glycer-
aldehyde-3-phosphate dehydrogenase, lactate dehy-
drogenase (Gapdh), cytoskletal protein b-actin-like
protein 2 (Actbl2), recoverin (Rcvrn), peroxiredoxin
2, serotransferrin (Tf) and a-2-macroglobulin (Pzp)
was also reduced. At the same time the level of Gri-
fin, ferritin L and H chains and b-crystallin A1
(Cryba1) increased in TG2 KO PVR samples. When
the changes upon dispase injection in WT and
TG2KO mice were compared (Fig. 3), among the
studied proteins four of them were changed in both
WT and TG2 KO mice. The level of tubulin b-5
decreased upon dispase treatment independently of
the presence of TG2, while the decrease in the level
of Grifin, Cryba1 and a-crystallin A observed in
WT mice changed to an increase in the TG2 KO
mice as a response to dispase injection. In the case
of a-crystallin A there was one spot where reduction
in the protein amount could be detected in dispase-
treated TG2 KO mice.
Discussion
Based on current knowledge, many cell types and vari-
ous factors appear to have a role in PVR pathogenesis.
RPE cells exposed to the vitreous upon retinal detach-
ment or retinal injury, migrate and proliferate giving
rise to fibroblast-like cells that are responsible for pro-
duction of ECM components and a repair membrane
[27–29]. Collagen, fibronectin and growth factors are
then produced by activated cells (M€uller glia, macro-
phages, modified RPE cells) or originate from the
serum itself to further enhance the proliferation and
migration of RPE cells and hence the epithelial-
to-mesenchymal transition – a key phenomenon in
PVR formation [4,29,30].
In a mouse model of PVR the intravitreal injection
of the proteolytic enzyme was used to activate RPE
cells [23]. Upon dispase treatment, the most prominent
changes were related to different forms of crystallins.
They function as chaperones, have protective roles [31]
and their increased levels were found to be associated
with intensive cell proliferation. Expression of Cryab
has been found to be higher in tongue carcinoma com-
pared with normal Ctrl tissue [32], overexpression of
Cryab was found to be protective in retinal epithelial
cells against stress-induced apoptosis [33], while at
gene expression level, the amount of a-, b- and c-crys-
tallin increased in the retina after injury [34–36]. Secre-
tion of Cryab in exosomes has recently been
Fig. 1. Fused image generated by the
superposition of WT Ctrl and WT PVR gel
images using DELTA2D software. The
numbered spots were found to have
significantly different intensities between
the groups.
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demonstrated [37], and thus it seems logical to have
this protein released into the vitreous after retinal
detachment, a phenomenon that often precedes the
PVR formation. We here demonstrate for the first time
increased levels of Cryab in the vitreous upon dispase
treatment. It is not clear whether the increased crys-
tallin level inhibits apoptosis of RPE cells via caspase
3 and 6 inhibition [38] and thus shifts the balance
toward RPE cell proliferation or if the proliferating
RPE cells produce and release more crystallin into the
vitreous, which further enhances and sustains the RPE
cell proliferation; in both scenarios, however, the result
is a decreased apoptosis and increased RPE cell prolif-
eration [33]. In our study, the crystallins, especially a-
crystallin A, show an extensive post-translational mod-
ification upon dispase treatment; almost half of the
spots containing some forms of crystallin contained a-
crystallin A. There is evidence that in oxidative stress
conditions following ischemia–reperfusion injury the
amount and post-translational modifications of
Table 1. List of identified proteins in spots showing significantly changed intesity upon dispase injection in WT mice. The name of the
identified protein, the spot number and fold change (WT PVR vs. WT Ctrl) value are indicated.
Spot ID Protein ID Protein name Fold change P
WT1 P99024 Tubulin b-5 chain 0.23 0.03
WT2 Q04447 Ckb 0.27 0.03
WT3 P62874 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit b-1 0.11 0.02
WT4 P62874 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit b-1 0.08 0.03
WT5 P24622 a-Crystallin A chain 0.23 0.02
WT6 O35737 Hnrnph1 0.09 0.049
WT7 O35737 Hnrnph1 0.11 0.04
WT8 P17182 Eno1 0.21 0.049
WT9 P15105 Glul 0.41 0.049
WT10 P14602 Hspb1 0.32 0.02
WT11 P02525 Cryba1 0.17 0.01
P62696 Crybb2
WT12 P02525 Cryba1 0.37 0.046
P62696 Crybb2
WT13 P62696 Crybb2 0.46 0.01
P02525 Cryba1
Q9JJV1 b-Crystallin A2
WT14 P02525 Cryba1 0.37 0.04
P62696 Crybb2
WT15 P02525 Cryba1 0.41 0.01
WT16 P24622 a-Crystallin A chain 0.51 0.02
Q9JJV1 b-Crystallin A2
WT17 P24622 a-Crystallin A chain 0.50 0.001
P02525 Cryba1
WT18 P02525 Cryba1 0.32 0.04
P24622 a-Crystallin A chain
WT19 P02525 Cryba1 0.25 0.01
WT20 P02525 Cryba1 0.11 0.03
WT21 P23927 Cryab 0.27 0.02
WT22 O35486 Crygs 0.34 0.01
P04344 c-Crystallin B
WT23 P62696 Crybb2 0.36 0.0002
WT24 P2392 Cryab 0.44 0.03
O35486 Crygs
Q61597 c-Crystallin C
WT25 P24622 a-Crystallin A chain 0.47 0.03
WT26 P24622 a-Crystallin A chain 0.28 0.02
WT27 P24622 a-Crystallin A chain 0.49 0.02
WT28 P24622 a-Crystallin A chain 0.25 0.02
WT29 Q9D1U0 Grifin 0.53 0.003
WT30 Q05816 Fatty acid-binding protein, epidermal 0.25 0.004
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Dispase treated TG2 knock-out mice samples
Saline treated TG2 knock-out mice samples
6_jv
A
B
12_jy 9_ml
3_7m 4_6Q
Fig. 2. Fused image generated by the superposition of TG2KO Ctrl and TG2KO PVR gel images using DELTA2D software. (A) Image
containing all spots. The numbered spots were found to have significantly different intensities between the groups. (B) Different spot
pattern observed on the individual examined gels with emphasis on basic pH and lower molecular mass region.
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crystallins are changed [38]. The pathophysiological
conditions leading to post-translational modifications
can only be speculated upon, hypothesizing the effect
of MMPs and dispase, respectively, but to best of our
knowledge, no experiments aiming to elucidate the
phenomena behind the crystallin profile changes have
been carried out.
The proteomic analysis of rat and rabbit PVR
models have revealed the down-regulation of colla-
gen-Ia1, a-1-antiproteinase and peroxiredoxin-2
(Prdx2) in rabbit vitreous, and up-regulation of
different forms of a-crystallin A, Tf, b-crystallin B2
(Crybb2), matrix metalloproteinase-3 and other pro-
teins in rabbit retina [39,40]. The amount of the
Eno1, vimentin, albumin and prohibitin was
increased, while the amount of tubulin b-2C, fructose-
bisphosphate aldolase A and other proteins was
reduced in the retina of animals after retinal detach-
ment [22]. In the case of these models the PVR
induction was done either by mechanical injury or by
retinal detachment surgery and the examined sample
was rabbit retina or vitreous [22,39,40].
Table 2. List of identified proteins in spots showing significantly changed intesity upon dispase injection in TG2KO mice. The name of the
identified protein, the spot number and the fold change (TG2KO PVR vs. TG2KO Ctrl) value are indicated.
Spot ID Protein ID Protein name Fold change P
TG2KO1 P99024 Tubulin b-5 chain 5.57 0.003
P68373 Tubulin a-1C chain
TG2KO3 P24622 a-crystallin A chain 76.45 0.01
TG2KO7 P70333 Heterogeneous nuclear ribonucleoprotein H2 9.51 0.003
TG2KO14 P09528 Fth1 5.82 0.04
TG2KO15 P24622 a-Crystallin A chain 6.28 0.005
TG2KO16 Q8BFZ3 Actbl2 7.01 0.01
TG2KO18 P02525 Cryba1 41.04 0.05
TG2KO19 P02525 Cryba1 5.13 0.01
TG2KO20 P24622 a-Crystallin A chain 49.71 0.01
TG2KO26 P24622 a-Crystallin A chain 128.66 0.02
TG2KO27 P02525 Cryba1 4.25 0.03
TG2KO31 P34057 Rcvrn 18.90 0.02
TG2KO33 P16125 L-Lactate dehydrogenase B chain 7.59 0.007
TG2KO34 P24622 a-Crystallin A chain 106.31 0.005
TG2KO38 Q61171 Prdx2 7.51 0.001
TG2KO42 Q61838 Pzp 20.54 0.0002
TG2KO44 P24622 a-Crystallin A chain 196.24 0.006
TG2KO47 P29391 Ferritin light chain 1 56.65 0.04
TG2KO48 P24622 a-Crystallin A chain 9.03 0.01
TG2KO49 P24622 a-Crystallin A chain 17.14 0.02
Q9D1U0 Grifin
TG2KO50 P24622 a-Crystallin A chain 8.92 0.02
TG2KO51 P24622 a-Crystallin A chain 83.15 0.003
TG2KO55 P24622 a-Crystallin A chain 31.65 0.03
TG2KO60 P16858 Gapdh 13.74 0.0002
TG2KO64 P24622 a-Crystallin A chain 42.28 0.0005
TG2KO67 P24622 a-Crystallin A chain 18.79 0.02
TG2KO70 P24622 a-Crystallin A chain 22.95 0.0005
TG2KO74 P24622 a-Crystallin A chain 88.39 0.03
TG2KO77 P24622 a-Crystallin A chain 31.74 0.005
TG2KO83 P62880 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit b-2 16.39 0.0001
TG2KO84 P24622 a-Crystallin A chain 12.72 0.01
TG2KO87 P24622 a-Crystallin A chain 21.14 0.0006
TG2KO88 P24622 a-Crystallin A chain 36.78 0.0007
TG2KO90 P24622 a-Crystallin A chain 11.36 0.004
P02525 Cryba1
P35700 Peroxiredoxin-1
TG2KO91 P06151 L-Lactate dehydrogenase A chain 22.83 0.0005
TG2KO94 Q921I1 Tf 7.40 0.0005
TG2KO96 P24622 a-Crystallin A chain 23.98 0.0002
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The differentially expressed proteins upon dispase
injection in WT mice, except Hnrnph1, Glul, ferritin H
chain, Cryba1 and Grifin, were also found in human
vitreous proteome [13]. The level of Crybb2 and S was
reduced in mice in accordance with published human
data; using MS the above-mentioned crystallin forms
were detected in donors but not in patients with PVR
[19]. In human vitreous proteome of patients with pro-
liferative diabetic retinopathy, a decrease in the
amount of a-crystallin A, b-crystallin S (Crygs), tubu-
lin b and creatin kinase B was observed [41] suggesting
the possible implication of these proteins in the prolif-
erative conditions; however, it is not known if their
reduced level is the cause or the consequence of the
proliferative state.
One of the methods used to examine the function of
a gene or protein is by removing the gene by knocking
it out from the genome [42]. This KO technology can
be used to study the function of various genes [43] and
in our study we have chosen to examine the function
of TG2 in PVR.
TG2, having transglutaminase, kinase and deami-
dase activities, can modify more than 300 different
substrates [44], and can interact with numerous
proteins (http://genomics.dote.hu/wiki) having a role
in different physiological processes such as ECM
remodeling [5] and wound healing [45]. Transglutami-
nase activity is known to be present in the eye [46]; as
a protein crosslinker, TG2 may participate in cell
adhesion in various ocular diseases such as allergic
conjunctivitis [47], abrasion, cataract [48] and glau-
coma [49]. TG2 was found in PVR membranes and it
was shown to modulate the phenotype and migration
of RPE cells and Ctrl the ECM remodeling in PVR
[5,50]. Our working hypothesis was that the crosslink-
ing activity of TG2 may prevent the appropriate
degradation of ECM proteins by the elevated protease
activities, and therefore may contribute to the PVR
development.
In order to study the role of TG2, a TG2 KO ani-
mal was created and PVR formation was examined in
the absence of TG2. Interestingly, in spite of the
marked protein profile changes (see below), OCT
examinations suggested the formation of PVR (data
not shown). It is not excluded, however, that TG2
may affect the timing of PVR formation but we do
not have such information as we examined the already
formed PVR condition only.
In the TG2 KO animals, the dispase treatment
resulted in altered crystallin network; the a-crystallin
A and Cryab levels were increased. Both a crystallin A
and B have been previously shown to be capable of
inhibiting apoptosis [38], and they might supplement
each other’s function.
In the TG2 KO PVR samples, compared with the
WT PVR samples, a different crystallin profile
change was seen, yet the pathological outcome
appeared to be the same at the time point of the
analysis. TG2 has different substrates that it can
bind to [44,51], and therefore, depending on which
one of these substrates is available for binding to it
under different pathological conditions, it is not
unexpected to induce an altered crystallin profile.
These data indicate that more than one type of
change in the profile of crystallins might be associ-
ated with PVR in mice. Crystallin changes have been
observed in general in the case of proliferative dis-
eases [31] and most probably the crystallin profile
changes are not specific to PVR. According to the
data presented in the literature, it cannot be judged
if the crystallin profile changes are the cause or the
consequence of a proliferative disease.
The crystallins identified in the different spots, hav-
ing various pI values and sizes, most probably are the
result of extensive post-translational modifications
affecting both the size and the net charge of the pro-
tein [52]. Such modifications might result in spots
Ckb ↓
Cryab↑
Cryba2↓
Crybb2↓
Crygb↓
Crygc↓
Crygs↓
Eno1 ↓
Fabp5↓
Glul ↓
Gnb1 ↓
Hnrnph1 ↓
Hspb1↓
Actbl2 ↓
Fth1 ↑
Ftl1 ↑
Gapdh ↓
Gnb2 ↓
Hnrnph2 ↓
Ldha ↓
Ldhb ↓
Prdx1 ↑
Prdx2 ↓
Pzp ↓
Rcvrn ↓
Tf ↓
Tuba1c ↓
Cryaa ↓↑↓
Cryba1 ↓↑
Grifin ↓↑
Tubb5 ↓↓
WT PVR TG2 PVR
Fig. 3. Summary of proteomic results of the proteins showing
significant alterations in their amount upon dispase treatment.
Black and red arrows show the direction of changes in WT and in
TG2 KO samples, respectively, upon dispase treatment, compared
with the physiological saline treated samples. The black arrows
refer to the changes in the WT mice while the red arrows show
the changes in the TG2 KO mice upon dipsase treatment. The
abbreviations of protein names are used according to gene name.
Cryaa, a-crystallin A chain; Cryba2, b-crystallin A2; Crygb, c-
crystallin B; Crygc, c-crystallin C; Fabp5, fatty acid-binding protein,
epidermal; Ftl1, ferritin light chain 1; Gnb1, guanine nucleotide-
binding protein G(I)/G(S)/G(T) subunit b-1; Gnb2, guanine
nucleotide-binding protein G(I)/G(S)/G(T) subunit b-2; Hnrnph2,
heterogeneous nuclear ribonucleoprotein H2; Ldha, L-lactate
dehydrogenase A chain; Ldhb, L-lactate dehydrogenase B chain;
Prdx1, peroxiredoxin-1; Tuba1c, tubulin a-1C chain; Tubb5, tubulin
b-5 chain.
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showing opposite intensity changes containing the
same protein. In TG2 KO PVR mice, the dispase
injection led to increased a-crystallin A amounts
observed in spots 2, 9, 10, 14, 17, 19, 21, 22, 23, 25,
26, 27, 28, 29, 31, 32, 33 and 37 and decreased
amounts observed in spot 5 indicating the presence of
the extensive post-translational modifications.
Taking into account that dispase is a protease and
TG2 is a crosslinking enzyme generating protease-
resistant isopeptide bonds, one may speculate that in
the absence of TG2, the proper crosslinks cannot be
formed, which might result in increased crystallin
cleavage by dispase. This may be the reason why some
spots containing a-crystallin are present in the lower
molecular mass region of the TG2 KO PVR gels. The
present study did not test this possibility; further
research is needed to clarify the situation. It is likely
that these differences will shine light on the different
substrates that may play a role in the pathogenesis of
PVR in vivo.
In the TG2 KO mice the dispase injection led to
increased amounts of ferritin heavy and light chains.
Ferritin maintains the iron homeostasis by limiting the
level of Fe (II) able to participate in the formation of
reactive oxygen species, thus protecting against oxidant
toxicity [53]. In the TG2 KO PVR samples, the inten-
sity of ferritin light chain-containing spots exceeded by
almost 10 times the intensity of ferritin heavy chain
(Fth1)-containing spots, which can be indicative of
oxidative stress.
Conclusion
The examination of protein profile changes in the dis-
pase-induced mouse model of PVR by 2D elec-
trophoresis followed by image analysis and subsequent
HPLC-MS/MS-based protein identification has shown
extensive changes related to crystallin proteins in dis-
pase-injected mice vitreous. To demonstrate the utility
of this mouse model for functional studies, the dispase
treatment was carried out on TG2KO mice and the
model was used successfully to get more information
on the protein profile changes in PVR in the lack of
TG2. TG2 appears to be responsible for the remodel-
ing of protein networks with alterations in stress man-
agement, indicating a possible protective role of TG2
in the resolution of stress during PVR pathogenesis.
The study provides further evidence on the utility and
applicability of the dispase-induced mouse model for
studying PVR, which can further help in understand-
ing the pathomechanism of the disease, and provide a
dynamic system for drug discovery and testing.
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